Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.39 |
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8624098 | 1.00 | LSS (0.40) | LSSS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL8622789 | 0.96 | S1PR2 (0.41) | LSSS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL8622799 | 0.96 | S1PR2 (0.41) | LSSS1PR2S1PR4S1PR1S1PR3 | |
| SCHEMBL8621102 | 0.94 | ANPEP (0.40) | ANPEPERAP1ERAP2ACP3 | |
| SCHEMBL8621189 | 0.94 | ANPEP (0.40) | ANPEPERAP1ERAP2ACP3 | |
| SCHEMBL8621107 | 0.94 | ANPEP (0.40) | ANPEPERAP1ERAP2ACP3 | |
| SCHEMBL27396721 | 0.93 | ANPEP (0.39) | ANPEPERAP1ERAP2ACP3 | |
| SCHEMBL27416174 | 0.93 | ANPEP (0.39) | ANPEPERAP1ERAP2ACP3 | |
| SCHEMBL8620886 | 0.92 | TRPV1 (0.43) | — | |
| SCHEMBL8620890 | 0.92 | TRPV1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | claimed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | claimed |
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |
| EP-0595635-A1 | Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors | E.R. Squibb & Sons, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |